Drug Trial Radar · NCT02783482
Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
Last checked: Nov 19, 2026Latest source record: Dec 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
Oct 2016
Primary completion
Jul 2019
Study completion Jul 2019
Sponsor
- Lead sponsor
- Green Cross CorporationIndustry
- Sponsor type
- Industry
- Collaborators
- Parexel; Atlantic Research Group
- First posted
- May 26, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in subjects with Primary Humoral Immunodeficiency (PHID).
Conditions
- Immunologic Deficiency Syndromes
Interventions
GC5107Biological
GC5107 20g/200mL, intravenously, dose of 300 - 900 mg/kg (of body weight) every 21 or 28 days for 12 months, a follow-up (3 or 4 weeks)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Incidence of Acute Serious Bacterial Infections (SBI)Time frame: One year
- The Proportion of Infusions With Temporally Associated Adverse Events (TAAEs) That Occur Within 72 Hours Following an Infusion of Test ProductTime frame: Within 72 hours after an infusion of GC5107
Locations
20 sites in 2 countries. Site status is shown where the registry gives one.
Immuno International Research Centers
Centennial, Colorado
Allergy Associates of Palm Beaches PA
North Palm Beach, Florida
Midwest Immunology Clinic and Infusion Center
Plymouth, Minnesota
Optimed Infusions LLC
Columbus, Ohio
Oklahoma Institute of Allergy Ashma and Immunology
Oklahoma City, Oklahoma
Allergy Partners of North Texas Research
Dallas, Texas
Allergy and Asthma Specialists
Dallas, Texas
Pediatric Pulmonary Associates of North Texas
Frisco, Texas
Allergy Asthma and Immunology Clinic PA
Irving, Texas
Lysosomal Rare Disorder Research and Treatment Center, Inc.
Fairfax, Virginia
University of Alberta Hospital
Edmonton, Alberta, Canada
Hamilton Health Sciences Corporation
Hamilton, Ontario, Canada
Queen's University - Kingston General Hospital (KGH)
Kingston, Ontario, Canada
The Ottawa Hospital
Ottawa, Ontario, Canada
Gordon Sussman Clinical Research
Toronto, Ontario, Canada
Saint Michael's Hospital
Toronto, Ontario, Canada
Hotel Dieu de Montreal
Montreal, Quebec, Canada
CHU Ste-Justine - University of Montreal
Montreal, Quebec, Canada
McGill University Health Centre (MUHC) - The Montreal Children's Hospital
Montreal, Quebec, Canada
Clinique Spécialisée en Allergie de la Capitale
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.